LONDON: AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts). Neogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US. AstraZeneca has acquired all outstanding equity of Neogene…
Tag: AstraZeneca
AstraZeneca partners LBT Innovations for APAS pharma development
ADELAIDE, AUSTRALIA: Australian medical technology company LBT Innovations Limited (ASX: LBT) has been engaged by AstraZeneca for the full product development for its APAS Pharma product. LBT Innovations has been engaged by AstraZeneca, a global biopharmaceutical company, to undertake a full product development project for the Company’s new APAS® Pharma analysis module (artificial intelligence software)…
AstraZeneca announces sale of West Chester site
LONDON, United Kingdom: AstraZeneca announced the sale of its West Chester site in Ohio, US, to National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines. Andrew Wirths, Senior Vice President, Americas Supply Region, AstraZeneca, said: “As part of our long-term strategy to ensure our global supply network remains fit…
AstraZeneca has completed the acquisition of TeneoTwo
LONDON: AstraZeneca has completed the acquisition of TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.1 AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. Financial considerations AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m. Under…
Oxford Biomedica signs new three year agreement with AstraZeneca
OXFORD, UK: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement with AstraZeneca UK Ltd which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine. This represents an expansion of the…
Imfinzi combo granted Priority Review for BTC
LONDON: AstraZeneca‘s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC), a statement noted. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved,…
AstraZeneca plans new R&D centre in Massachusetts
LONDON: AstraZeneca today announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub. The new site will be a strategic R&D centre for AstraZeneca, as well as Alexion’s new corporate headquarters. The site will bring together approximately 1,500 R&D, commercial and corporate colleagues into a single purpose-built space in Kendall…
AstraZeneca’s Tremelimumab accepted under Priority Review in the US
LONDON: AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single priming dose of the anti-CTLA4 antibody added to Imfinzi (durvalumab) for the treatment of patients with unresectable hepatocellular carcinoma (HCC). A supplemental BLA (sBLA) has also been submitted for Imfinzi in this indication. This novel dose…
Lynparza approved in US for early breast cancer
LONDON: AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. The approval by the US Food and Drug Administration (FDA) was based on results from the OlympiA Phase…
AstraZeneca and Neurimmune close deal for NI006
LONDON: Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis….